Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through
|
|
- Meryl Brown
- 6 years ago
- Views:
Transcription
1 Research Article ISSN: Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through Comparison of efficacy and safety of Cinacalcet versus Calcitriol in patients of secondary hyperparathyroidism in Indian population. *Amol K Choulwar 1, Ashish A Mungantiwar 2, Meena Chintamaneni 3 1 R & D Center, Macleods Pharmaceuticals Ltd, G-2, Mahakali Caves Road, Shanti Nagar, Andheri-East. Mumbai , Maharashtra, India. 2 R & D Center, Macleods Pharmaceuticals Ltd, G-2, Mahakali Caves Road, Shanti Nagar, Andheri-East. Mumbai , Maharashtra, India. 3 School of Pharmacy and Technology Management, Narsee Monjee Institute of Management & Higher Studies, Vile Parle (west), Mumbai , Maharashtra, India Received on: ; Revised on: ; Accepted on: ABSTRACT Treatment of secondary hyperparathyroidism with vitamin-d and calcium in patients receiving dialysis is often complicated by hypercalcemia and hyperphosphatemia, which may contribute to cardiovascular disease and adverse clinical outcomes. Calcimimetic agents (Cinacalcet) act on the calciumsensing receptor and lower parathyroid hormone (PTH) levels without increasing calcium and phosphorus levels. We report the results of our comparative, open, randomized and prospective clinical trial conducted in Indian population evaluating the effectiveness and safety of cinacalcet hydrochloride. Patients with chronic kidney disease (CKD) and who had inadequately controlled secondary hyperparathyroidism despite standard treatment were randomly assigned to receive cinacalcet (28 patients) or calcitriol (20 patients) for 24 weeks. Once-daily doses of cinacalcet were increased from 30 mg to 180 mg to achieve PTH levels of 250 pg per milliliter or less. The primary end point was decrease in the PTH levels (The percent change from base line) of patients at the end of treatment. Mean PTH level in patients treated with Cinacalcet was significantly decreased from pg/ml to pg/ml (i.e %) and from pg/ml to pg/ml (i.e %) in Calcitriol treated patients at the end of treatment. Also Mean Serum calcium level in patients treated with Cinacalcet was decreased from 8.83 mg/dl to 8.07 mg/dl (i.e. 8.61%) and from 8.76 mg/dl to 8.72 mg/dl (i.e. 0.46%) in Calcitriol group. Cinacalcet effectively reduced PTH levels independently of disease severity or changes in vitamin D sterol dose and improves calcium phosphorus homeostasis in CKD patients who have uncontrolled secondary hyperparathyroidism. Keywords: Secondary Hyperparathyroidism, Cinacalcet, Calcitriol, Parathyroid Hormone, Chronic Kidney Disease. INTRODUCTION: Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease, affecting most of those who are receiving hemodialysis. [1, 2] The disorder is characterized by persistently elevated levels of parathyroid hormone and complicated by important disturbances in mineral metabolism. [3] Bone disease is the most widely recognized consequence of secondary hyperparathyroidism. [4] Several reports indicate, however, that alterations in calcium and phosphorus metabolism, as a result of either secondary hyperparathyroidism or the therapeutic measures used to manage it, contribute to soft-tissue and vascular calcification, cardiovascular disease, and the risk of death. [5-10] Episodes of hypercalcemia and hyperphosphatemia are often aggravated by the use of large doses of calcium as a phosphate-binding agent, particularly in combination with vitamin D sterols, which increase the absorption of calcium and phosphorus. [10-13] Conventional management of SHPT includes the provision of active vitamin-d derivatives and phosphate binders (Ca and non Ca-based). Although active vitamin D derivatives are effective in reducing PTH levels, their use may exacerbate hypercalcemia and hyperphosphatemia as a result of enhanced intestinal Ca and P absorption. [32] *Corresponding author. Amol Choulwar Dy.Manager-Medical Services R & D Center, Macleods Pharmaceuticals Ltd, G-2, Mahakali Caves Road, Shanti Nagar, Andheri-East. Mumbai , Maharashtra, India Tel.: amolchoulwar@gmail.com Therefore, despite the use of phosphate binders and active vitamin D derivatives, the majority of hemodialysis patients fail to achieve all four targets (PTH, Ca, P, and the Ca-P product [Ca _ P]) recommended by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines. [33,34] There is thus considerable interest in identifying therapeutic alternatives that control secondary hyperparathyroidism while limiting these side effects. The calcium-sensing receptor regulates the secretion of parathyroid hormone. [14] Calcimimetic agents increase the sensitivity of the calciumsensing receptor to extracellular calcium ions. [15,16] Inhibit the release of parathyroid hormone, and lower parathyroid hormone levels within a few hours after administration. [17-19] Calcimimetics bind to the Ca-sensing receptor, a G protein coupled receptor that is present on the parathyroid gland. [35] The calcimimetics, such as cinacalcet HCl, allosterically modulate the Ca-sensing receptor, increasing its sensitivity to extracellular Ca and thereby decreasing PTH synthesis and secretion from the parathyroid gland. [36,37] Cinacalcet reduces PTH with simultaneous decreases in both serum concentrations of Ca and P. [38,39] This mechanism of action differs fundamentally from that of vitamin-d sterols, which diminish the transcription of the parathyroid hormone gene and hormone synthesis over a period of many hours or several days. [20] Results of small clinical trials indicate that the calcimimetic agent cinacalcet hydrochloride not only reduces parathyroid hormone levels but also lowers serum calcium and phosphorus levels in patients with secondary hyperparathyroidism. [21-23] Calcitriol is the most active known form of vitamin D3 is act on parathyroid gland & in stimulating intestinal calcium transport. Calcitriol has been shown to stimulate intestinal calcium absorption.
2 Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), In order to determine whether Cinacalcet provides a therapeutic advantage to Calcitriol, this open, randomized, prospective, phase III study in Indian patients with Secondary hyperparathyroidism was undertaken. Here, we report the results of phase-iii clinical trial of Cinacalcet Versus Calcitriol in Indian patients with Secondary hyperparathyroidism. MATERIALS AND METHODS: Study candidates were patients in medically stable condition with secondary hyperparathyroidism who were 18 years of age or older and were Predialysis patients suffering from CKD. The primary eligibility criterion was a mean plasma parathyroid hormone level of at least 200 pg per milliliter, established by measurements obtained within a screening period. Also patients with Serum calcium >7.1 mg/ml and <11.0 mg/dl, Serum phosphorus > 2.5 mg/dl and Patients willing to provide informed consent to be included in the study. Exclusion criteria included evidence of cancer, active infection, diseases known to cause hypercalcemia, or a serum calcium level below 8.4 mg per deciliter (2.1 mmol per liter), corrected for albumin. Because cinacalcet can inhibit cytochrome P-450 2D6, patients were excluded if they were receiving drugs such as flecainide, thioridazine, and most tricyclic antidepressants, which have a narrow therapeutic index and are metabolized by this enzyme. Also Pregnant or Lactating females, Female Patient with childbearing age not using medically approved contraceptives, Patient with known suspected history of hypersensitivity to Cinacalcet, Patients with impaired liver function, defined as SGOT or SGPT > 2.0 times the upper limit of normal and Patients with unstable clinical condition were excluded from the study. The study protocols were reviewed and approved by the institutional review board at each study site, and written informed consent was obtained from each patient before enrollment. The complete data set was held at the Macleods Pharmaceuticals Ltd. Statistical analyses and data interpretation were conducted in biostatistics department at Macleods Pharmaceuticals Ltd. The investigators had unrestricted access to the primary data and were not limited by the sponsor with regard to statements made in the final article. Study Design Comparative, open, randomized and prospective clinical trials were conducted at three sites in India. Patients were randomly divided into two groups. Each patient as per randomization was received either group A (Cinacalcet) or group B (Calcitriol) for a period of 24 weeks. Assessment of Safety Post-Study Examination Physical examination, Clinical examination and pathology laboratory tests were performed to cater to the post study safety assessments at the end of visit-7. Patients Monitoring During the Study During each follow-up visit i.e. on week4, week8, week12, week16, week 20 and week 24 vital signs & clinical examinations was carried out. Assessment of vital signs could also be done, if the principle investigator finds it necessary at any time during the conduct of the study. In case of any abnormality in vital signs, abnormal pathology lab reports or any adverse events observed during the study, principle investigator could take the decision whether the patients would be continued in the study or not. Study End Points Assessment of Clinical Efficacy I) Clinical Efficacy was graded as follows: a] Improved: Improvement in signs and symptoms at the end of therapy. b] Failure: Either worsening or no improvement of signs and symptoms at the end of therapy. II) Decrease in the PTH levels (The percent change from base line). III) Decrease in the calcium, phosphorus and calcium X phosphorus at the end of treatment (The percent change from base line). Patient Dropout Patients who have not completed the therapy were considered as drop out cases. The reason for the drop out was properly recorded in CRF. Statistical Analysis Data was analyzed using appropriate statistical test such as z- test, ANOVA and Chi-Square test. The value of p<0.05 was considered as statistically significant. The values of efficacy parameters were presented as Mean ± SD. Base-line laboratory measurements were obtained and patients characteristics were noted during the screening period. Mean values for parathyroid hormone, calcium, phosphorus, and the calcium phosphorus product during the efficacy-assessment phase were calculated with the use of all available results from each patient. RESULTS: Total 50 patients were enrolled in the study and were randomly assigned to receive cinacalcet (28 patients) or Calcitriol (22 patients). The initial dose of cinacalcet is 30 mg (once a day), Increased sequentially every four weeks to 60, 90, 120 & 180 mg once daily and Clacitriol is 0.25 mcg daily, May be increased by 0.25 mcg daily at intervals of 4-8 weeks. The dose was reduced if parathyroid hormone levels were less than 100 pg per milliliter (10.6 pmol per liter) on three consecutive study visits or if patients reported an adverse event requiring. Dose adjustments were permitted at four-week intervals during the efficacy assessment phase. Patients were allowed to continue receiving vitamin-d sterols during this study if they were prescribed. Therefore, guidance was provided for changes in the dose of vitamin-d. Patients were also permitted to continue to receive phosphate-binding agents and participate in this study. Increases in the dose of vitamin D sterols were permitted if parathyroid hormone levels rose by 50 percent or more from base line. Biochemical Determinations Plasma parathyroid hormone levels and serum calcium and phosphorus levels were measured at each study visit. Biochemical measurements were made at central reference laboratory. I) Demographic Characteristics Mean age of the patients was years for Cinacalcet treated group and for Calcitriol treated group. Average weights of the patients were Comparable. The mean weight of patients was kg & respectively. Out of 50 patients, 35 patients were males and the remaining 15 were females. A total of 50 patients were enrolled in the study. II) Drop Outs and Managements There were two patients drop out from Calcitriol group. All 48 patients completed the study were included for statistical analysis. III) Baseline Characteristics The mean body temperature was F for patients on Cinacalcet therapy & F for patients on Calcitriol therapy at basal and F and F temperature at the end of study in Cinacalcet and Calcitriol group respectively. There was no statistically significant difference between these groups (p>0.05). During and after the treatment, mean body temperature did not show any significant changes in both the groups. The mean pulse-rate was 81.05/min for patients of Cinacalcet therapy and
3 75.58/min for patients of Calcitriol therapy at basal. At the end of therapy pulse-rate was 82.00/min and 76.91/min for patients of Cinacalcet therapy and Calcitriol therapy, respectively. There was no statistically significant difference between these groups (p>0.05). During and after the treatment, mean pulse-rate did not show any significant changes in both the groups. The average respiratory rate was 17.10/min for patients of Cinacalcet therapy & 16.33/min for patients of Calcitriol therapy at basal. At the end of treatment, the respiratory rate was found to be18.94/min for patients of Cinacalcet therapy & 18.75/min for patients of Calcitriol therapy. There was no statistically significant difference between these groups (p>0.05). During and after the treatment, mean respiratory rate did not show any significant changes in both the groups. The average Blood Pressure of patients treated with Cinacalcet was / mmhg and /78.00 mmhg of patients treated with Calcitriol at basal & /84.89 mmhg of Cinacalcet group and131.09/83.27 mmhg of patients with Calcitriol treated group after the 24 week treatment. There was no statistically significant difference between these groups (p>0.05). During and after the treatment, mean blood pressure did not show any significant changes in both the groups. IV) Efficacy Parameters Primary end point was achieved and following parameters were recorded a) PTH Levels: Mean PTH level for patients treated with Cinacalcet tablet was significantly decreased from pg/ml to pg/ml (i.e %) at the end of treatment. In the same line there was significant decreased PTH level from pg/ml to pg/ml (i.e %) for patients treated with Calcitriol tablet at the end of treatment. There was no statistically difference (p>0.05) for PTH level between the groups at the end of therapy. Table 1. Base-line demographic characteristics of patients (Group-A) (Group-B) No. of Patients Age (yrs)* ± ±12.82 Weight (Kg)* 55.25± ±13.26 Sex Male Female 6 9 p > 0.05 there was no statistical significant difference between the two groups.* By z-test (age & weight)± values = mean ± SD Table 2. Comparison of patients examination between two groups Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Table 3. Comparison in biochemical parameters between two groups Mean PTH Level Base Line (pg/ml) ± ± End of Therapy (pg/ml) ± ± Percent Change 24.64% 21.63% Mean Serum Calcium Level Base Line (mg/dl) 8.83 ± ± 0.45 End of Therapy (mg/dl) 8.07 ± ± 0.66 Percent Change 8.61% 0.46% Mean Serum Phosphorus Level Base Line (mg/dl) 4.65 ± ± 1.41 End of Therapy (mg/dl) 5.70 ± ± 1.26 Percent Change % -2.60% Calcium-Phosphorus Ratio Base Line ± ± End of Therapy 31.02± ± Percent Change -5.22% -0.09% z-test (between two groups)± values = mean ± SD Table 4. Global assessment of treatment by patients for efficacy Excellent Efficacy Number of Patients (%) 19 (67.86%) 06 (30.00%) Good Efficacy Number of Patients (%) 08 (28.57%) 11 (55.00%) Poor Efficacy Number of Patients (%) 01 (03.57%) 03 (15.00%) Chi-Square test PTH Level (pg/ml) Base Line End of Therapy Mean Body Temperature Base Line ( 0 F) ± ± 1.68 End of Therapy ( 0 F) 98.9 ± ± 1.3 Mean Pulse Rate Base Line (per minute) ± ± 7.66 End of Therapy (per minute) ± ± 5.45 Mean Respiratory Rate Base Line (per minute) ± ± 0.84 End of Therapy (per minute) ± ± 0.86 Mean Blood Pressure (Systolic) Base Line (mm Hg) ± ± End of Therapy (mm Hg) ± ± Mean Blood Pressure (Diastolic) Base Line (mm Hg) ± ± End of Therapy (mm Hg) ± ±6.92 z-test (between two groups)± values = mean ± SD 0 Cinacalcet Calcitriol Figure 1: Comparison of PTH Level between Baseline and End of Therapy values b) Serum Calcium Levels: Mean Serum calcium level for patients treated with Cinacalcet tablet was decreased from 8.83 mg/dl to 8.07 mg/dl (i.e. 8.61%) at the end of treatment. After the treatment with Calcitriol tablet decreased from 8.76 mg/dl to 8.72 mg/dl (i.e. 0.46%). There was no statistically difference (p>0.05) in serum calcium level between the groups at the end of therapy. c) Serum Phosphorus Levels: The mean serum phosphorus levels in patients treated with Cinacalcet was increased from 4.65mg/dL to 5.70mg/dL (i.e %) at the end of therapy and after the treatment with Calcitriol from 4.9 mg/dl to 5.03 mg/dl (i.e. 2.6%).
4 Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), d) Calcium X Phosphorus Level: The mean change in calcium x phosphorus level for patients treated with Cinacalcet tablet was increased from to (i.e 5.22%) at the end of therapy. Similarly there was comparable increased in calcium x phosphorus level after the treatment wit Calcitriol tablet from to (i.e. 0.09%). V) Laboratory Investigations The comparison of laboratory parameters hemoglobin, CBC, SGOT, SGPT, serum creatinine level, BUN, serum uric acid level, were done for both groups at basal & at the end of treatment. There were no statistically difference (p>0.05) during and after the treatment, within the group. DISCUSSION: Our results indicate that cinacalcet effectively reduces parathyroid hormone levels in patients with secondary hyperparathyroidism who are receiving hemodialysis and ameliorates disturbances in serum calcium and phosphorus that have been associated with adverse clinical outcomes. The use of vitamin D sterols to lower parathyroid hormone levels, particularly in combination with calcium-containing phosphate binders, can cause hypercalcemia and hyperphosphatemia by promoting intestinal absorption of calcium and [24, 25, 26, 27] phosphorus. These disturbances often interrupt treatment, leading to inadequate biochemical control and progression of bone disease. [26, 28] Such derangements are also associated with an increased risk of death, increased arterial stiffness, and calcification of the coronary arteries, aorta, and cardiac [8, 9, valves ] Thus, the fact that cinacalcet lowers parathyroid hormone levels while reducing serum calcium and phosphorus levels represents a potentially important therapeutic development. The study concluded that, patients treated with Cinacalcet show more improvement in the clinical efficacy parameters than Calcitriol. There were no serious adverse effects found throughout the study. Thus, Cinacalcet has the potential to reduce the prevalence of hyperparathyroidism and limit the potential toxicity of current treatment strategies. This study provides evidence that, Cinacalcet may clinically relevant pharmacologic approach to improve the Secondary hyperthyroidism symptoms and controling associated disturbances in mineral metabolism in patients who receive peritoneal dialysis (PD) or Hemodialysis (HD). ACKNOWLEDGEMENT The authors gratefully acknowledge Dr. Rajendra Agarwal, Managing Director, Macleods Pharmaceuticals Ltd for providing the necessary facilities. REFERENCES: 1. Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis, 29, 1997, Owda A. Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail, 25, 2003, Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl, 73,1999, S14-S Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med, 1995,333, Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium-phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis, 31, 1998, Ribeiro S, Ramos A, Brandao A, et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant, 13, 1998, Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med, 342, 2000, Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol, 39, 2002, Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Ca-PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol, 12, 2001, Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis, 35, 2000, Johnson CA, McCarthy J, Bailie GR, Deane J, Smith S. Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis, 39, 2002, Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int, 57, 2000, Maung HM, Elangovan L, Frazao JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alphahydroxyvitaminD2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis, 37, 2001, Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca2+ -sensing receptor from bovine parathyroid. Nature, 1993,366: Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA, 95,1998, Hammerland LG, Garrett JE, Hung BC, Levinthal C, Nemeth EF. Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol, 53, 1998, Fox J, Lowe SH, Conklin RL, Nemeth EF. The calcimimetic NPS R- 568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine, 10, 1999, Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int, 2000, 58: Silverberg SJ, Bone HG III, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med, 1997, 337: Brown EM. Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens, 2, 1993, Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol, 13, 2002, Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of endstage renal disease. J Am Soc Nephrol, 14, 2003, Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium-phosphorus in secondary hyperparathyroidism. Kidney Int, 2003, 63: Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int, 2000, 57: Maung HM, Elangovan L, Frazao JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alphahydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis, 37, 2001, Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int, 59, 2001,
5 27. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis, 29, 1997, Locatelli F, Cannata-Andia JB, Drueke TB, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant, 17, 2002, Ribeiro S, Ramos A, Brandao A, et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant, 13, 1998, Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med, 2000, 342: Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis, 35, 2000, Walling MW: Intestinal Ca and phosphate transport: Differential responses to vitamin D3 metabolites. Am J Physiol, 1977, 233, E488 E494, 33. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis, 2004, 44, 34 38, Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Source of support: Nil, Conflict of interest: None Declared 34. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003, 42[Suppl], S1 S201, 35. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca(2_)-sensing receptor from bovine parathyroid. Nature, 1993, 366, , 36. Levi R, Gaberman E, Silver J, Martin D, Naveh-Many T. The calcimimetic NPS R-568 decreases PTH gene expression in rats with secondary hyperparathyroidism due to experimental uremia [Abstract]. Nephrol Dial Transplant, 2005, 20, V Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther, 2004, 308, , 38. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, et al: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol, 2005,16, Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, et al: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med, 2004, 350,
HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationThe Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism
J Am Soc Nephrol 13: 1017 1024, 2002 The Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism WILLIAM G. GOODMAN,* GERALD A. HLADIK,
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Effect on mortality of elective parathyroid surgery in one hundred and three patients with chronic kidney disease : our experience. White Rose Research Online URL for this
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationSimultaneous Control of PTH and Ca P Is Sustained over Three Years of Treatment with Cinacalcet HCl
Simultaneous Control of PTH and Ca P Is Sustained over Three Years of Treatment with Cinacalcet HCl Stuart M. Sprague,* Pieter Evenepoel, Mario P. Curzi, Maria Teresa González, Fred E. Husserl, Nelson
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationMineral and bone disorder (MBD) affects the majority
Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients Mark D. Danese,* Vasily Belozeroff, Karen Smirnakis, and Kenneth J. Rothman *Outcomes Insights, Inc., Newbury Park, California;
More informationA calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication
Kidney International, Vol. 53 (1998), pp. 223 227 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication JOHN E. ANTONSEN, DONALD
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationPhosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer
Hemodialysis International 2015; 19:5459 Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Toru SANAI, 1
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationScholars Research Library
Available online at www.scholarsresearchlibrary.com Annals of Biological Research, 2011, 2 (3) : 35-50 (http://scholarsresearchlibrary.com/archive.html) ISSN 0976-1233 CODEN (USA): ABRNBW A comparative,
More informationCa, Phos and Vitamin D Metabolism in Pre-Dialysis Patients
Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More informationCost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA
Volume 11 Number 5 2008 VALUE IN HEALTH Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA Joshua A. Ray, MSc,
More informationCLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)
CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,
More informationNDT Advance Access published February 3, 2007
NDT Advance Access published February 3, 2007 Nephrol Dial Transplant (2007) 1 of 6 doi:10.1093/ndt/gfl840 Original Article Implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and
More informationSwiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide)
Swiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide) RMP Summary: Version 1, November 2017 EU RMP: Version 1.0, November 2016 Page 1 of 6 The Risk Management Plan (RMP) is a comprehensive
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationThe elevated parathyroid hormone (PTH) and disordered
Increased Parathyroid Hormone Gene Expression in Secondary Hyperparathyroidism of Experimental Uremia Is Reversed by Calcimimetics: Correlation with Posttranslational Modification of the Trans Acting Factor
More informationCinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
The new england journal of medicine original article for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis Geoffrey A. Block, M.D., Kevin J. Martin, M.B., B.Ch., Angel L.M. de Francisco,
More informationCorporate Presentation January 2013
Corporate Presentation January 2013 0 Forward-Looking Statements Certain statements and information included in this presentation are forwardlooking statements under the Private Securities Litigation Reform
More informationLong-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism
Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism Kazunori Nakayama 1, 2, Kazushi Nakao 1, 2, Yuji Takatori 1,
More informationEffect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
Research Article Effect of lanthanum and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease P. Thomas Scaria, Reneega Gangadhar 1, Ramdas Pisharody 2 ABSTRACT Departments
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationOriginal epidemiologic studies 1 have suggested that approximately
Factors for Increased Morbidity and Mortality in Uremia: Hyperphosphatemia Nathan W. Levin, Frank A. Gotch, and Martin K. Kuhlmann Hyperphosphatemia is a metabolic abnormality present in the majority of
More informationParsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1
Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1 Not an actual Parsabiv vial. The displayed vial is for illustrative
More informationPARSABIV (etelcalcetide)
PARSABIV (etelcalcetide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationParathyroid Hormone, Calcium and Phosphorus Levels in Hemodialysis Patients at Al-Shifa Hospital, Gaza-Palestine
IUG Journal of Natural and Engineering Studies Vol.22,No.1, pp 97-110 2014, ISSN 1726-6807, http://www.iugaza.edu.ps/ar/periodical/ Parathyroid Hormone, Calcium and Phosphorus Levels in Hemodialysis Patients
More information02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationInternational Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: Vol.7, No.4, pp ,
International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304 Vol.7, No.4, pp 560-565, 2014-2015 Comparison of Calcium, Phosphate and Intact Parathyroid Hormone Levels Pre- and Post-Parathyroidectomy
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationA new era in phosphate binder therapy: What are the options?
http://www.kidney-international.org & 2006 International Society of Nephrology A new era in phosphate binder therapy: What are the options? IB Salusky 1 1 Department of Pediatrics, David Geffen School
More informationSevelamer hydrochloride: a calcium- and metal-free phosphate binder
DRUG PROFILE Sevelamer hydrochloride: a calcium- and metal-free phosphate binder Anthony J Bleyer & James Balwit Author for correspondence Wake Forest University School of Medicine, Section on Nephrology,
More informationSensipar PRODUCT MONOGRAPH. (cinacalcet hydrochloride) Tablets 30 mg, 60 mg, 90 mg. Calcimimetic agent
PRODUCT MONOGRAPH Pr Sensipar (cinacalcet hydrochloride) Tablets 30 mg, 60 mg, 90 mg Calcimimetic agent Amgen Canada Inc. 6775 Financial Drive, Suite 100 Mississauga, Ontario L5N 0A4 Date of Revision:
More informationParsabiv (etelcalcetide) NEW PRODUCT SLIDESHOW
Parsabiv (etelcalcetide) NEW PRODUCT SLIDESHOW Introduction Brand name: Parsabiv Generic name: Etelcalcetide Pharmacological class: Calcimimetic Strength and Formulation: 2.5mg/0.5mL, 5mg/mL, 10mg/2mL;
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationReport and Opinion 2016;8(12)
Prevalence of calcific aortic valve stenosis in haemodialysis patients at AL Hussein University Hospital. Ahmed Alaa Saad 1, Sami H. Nooh 2, Osama A. Khamis 1, Magdy E. Mohamed 1, Mohamed Abdelhafez 1
More informationOutline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010
Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationHyperphosphatemia is associated with a
TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular
More informationNatpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary
Natpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 2 Available Product Indication Dosing and Administration Natpara (parathyroid hormone)
More informationUltrasound examination in diagnosis of morphological variants of parathyroid hyperplasia in patients with secondary hyperparathyroidism
Ultrasound examination in diagnosis of morphological variants of parathyroid hyperplasia in patients with secondary hyperparathyroidism Poster No.: C-0304 Congress: ECR 2015 Type: Authors: Keywords: DOI:
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 01 June 2007 Product Name : Renagel Procedure No: EMEA/H/C/000254/II/56 SCIENTIFIC DISCUSSION 1/11 1. Introduction Renagel (sevelamer), a non-absorbed, calcium and metal-free
More information... . : ... PTH.
IRMA Email msarookhani@qumsacir * CRD GFR D [1,25OH 2 D 3 ] SHPT GFR» «KDOQI SHPT Ca * P P P Selectra Overt HPT = = Ca * P P > GM II DSL i IRMA ± ± ± Ca * P % % % % % % % % % % % % % % % % pgml = = > ±
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson-Zachrisson, 3
More informationWhat Are the Targets in CKD-MBD?
Knowledge Exchange 2016 Paris, France, September 30, 2016 Date of preparation: Nov 2016 Item job code: INTSP/C-ANPROM/FOS/16/0025 Cristina Ortiz Jorge B Cannata-Andía Bone and Mineral Research Unit Hospital
More informationSince its inception in the 1970s, dialysis has allowed for
http://www.revistanefrologia.com 2013 Revista Nefrología. Official Publication of the Spanish Nephrology Society editorial comment See original article on page 46 Are the K/DOQI objectives for bone mineral
More informationSensipar (cinacalcet) Tablets
DESCRIPTION Sensipar (cinacalcet) is a calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. Its empirical formula is C 22 H 22 F 3 N
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationTotal Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism
The Journal of International Medical Research 2011; 39: 978 987 Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism J NARANDA 1,2, R EKART
More informationOriginal Article. Introduction
Nephrol Dial Transplant (2006) 21: 1663 1668 doi:10.1093/ndt/gfl006 Advance Access publication 6 February 2006 Original Article Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationEffectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients
Open Access Journal of Journal of Parathyroid Disease 2017,5(1),17 24 http://www.jparathyroid.com Original Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis
More information2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority
More informationClinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet:
Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: Results of a prospective randomized controlled study Forni Valentina¹, Pruijm Menno¹,
More informationComplications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease
Med Clin N Am 89 (2005) 549 561 Complications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease Shona Pendse, MD, Ajay K. Singh, MB, MRCP(UK)* Renal Division, Brigham and
More information2.0 Synopsis. ABT-358/Paricalcitol M Clinical Study Report R&D/09/1255. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Title of Study: Late Phase II Study of Paricalcitol Injection Dose-response study of paricalcitol injection in chronic kidney disease subjects receiving hemodialysis with secondary hyperparathyroidism
More informationCKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism
CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism Pieter Evenepoel Nephrology, Dialysis, and Transplantation University Hospitals Leuven April 2017, FMC Herbeumont Disclosures Research support:
More informationBiochemical and pathologic abnormalities are a common
CJASN epress. Published on March 4, 2009 as doi: 10.2215/CJN.03790808 Cinacalcet Lowers Serum Alkaline Phosphatase in Maintenance Hemodialysis Vasily Belozeroff,* William G. Goodman, Lulu Ren, and Kamyar
More informationDeterminants of coronary artery calcification in maintenance hemodialysis patients
1 Determinants of coronary artery calcification in maintenance hemodialysis patients Yoshiko Nishizawa, MD 1,2, Sonoo Mizuiri, MD, PhD 2, Noriaki Yorioka, MD, PhD 3, Chieko Hamada MD, PhD 1,Yasuhiko Tomino
More informationEffect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients
Nephrol Dial Transplant (2003) 18 [Suppl 3]: iii42 iii46 DOI: 10.1093/ndt/gfg1011 Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients Kazuhiro Shiizaki
More informationTreatment Options for Chronic Kidney
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson- Zachrisson,
More informationIntroduction/objective: Adinamic bone disease (ABD) is a common finding in peritoneal. dialysis (PD) and is associated with a
Original Article Low-calcium peritoneal dialysis solution is effective in bringing PTH levels to the range recommended by current guidelines in patients with PTH levels < 150 pg/dl Authors Thyago Proença
More informationVelphoro (sucroferric oxyhydroxide)
STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney
More informationTreatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)
Kidney International, Vol. 65 (2004), pp. 1914 1926 Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study) WAJEH Y. QUNIBI,ROBERT E. HOOTKINS,LAVETA
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationNatpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary
Natpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Agent Indication Dosing and Administration Natpara (parathyroid hormone) subcutaneous
More informationCost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients
original article http://www.kidney-international.org & 2007 International Society of Nephrology Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis
More informationIpovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano
Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale Maurizio Gallieni Università degli Studi di Milano G Ital Nefrol 2018 - ISSN 1724-5990 Nutrients 2017, 9, 328 Vitamin D deficiency (
More informationSlowing the Progression of Vascular Calcification in Hemodialysis
Slowing the Progression of Vascular Calcification in Hemodialysis J Am Soc Nephrol 14: S310 S314, 2003 GLENN M. CHERTOW Division of Nephrology, Department of Medicine, University of California San Francisco,
More informationPhosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis
IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and
More informationCinacalcet suppresses calcification of the aorta and heart in uremic rats
original article http://www.kidney-international.org & 28 International Society of Nephrology see commentary on page 1229 Cinacalcet suppresses calcification of the aorta and heart in uremic rats Takehisa
More informationDevelopment and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics
translational nephrology http://www.kidney-international.org & 2008 International Society of Nephrology Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from
More information